Merck: Keytruda meets endpoint in colorectal cancer trial

(CercleFinance.com) - Merck said that its drug Keytruda has met one of its primary endpoints in a Phase 3 analysis, showing progression-free survival for patients with advanced metastatic colorectal cancer.


The blockbuster cancer drug demonstrated a "statistically significant and clinically meaningful improvement" in progression-free survival compared with chemotherapy, the biopharmaceutical firm said.

The tests were conducted on patients with microsatellite instability-high or mismatch repair deficient unresectable or metastatic colorectal cancer, which represents approximately 10%-15% of colorectal cancer cases.

Merck said that the study will continue without changes to evaluate overall survival, the trial's other dual primary endpoint, which was not met.

Copyright (c) 2020 CercleFinance.com. All rights reserved.